Semaglutide: Side Effects

Safety Overview#

Semaglutide has been evaluated in the most extensive GLP-1 receptor agonist clinical trial program to date, including SUSTAIN (T2D injectable, >4,000 participants), PIONEER (T2D oral, >9,000 participants), STEP (obesity, >5,000 participants), and SELECT (cardiovascular outcomes, 17,604 participants). The safety profile is well characterized through these programs and over 7 years of post-marketing surveillance since the initial Ozempic approval in December 2017.

Gastrointestinal Adverse Events#

The most frequently reported adverse events with semaglutide are gastrointestinal, consistent with the GLP-1 receptor agonist mechanism of action. These effects are mediated through GLP-1R activation in the gut (gastric emptying delay, altered motility) and central nervous system (appetite suppression).

Nausea is the most common adverse event. In STEP 1 (2.4 mg Wegovy), nausea was reported in 44.2% of semaglutide patients versus 17.4% placebo. In SUSTAIN trials (0.5-1 mg Ozempic), rates were lower at 15-20%. Nausea is dose-related, predominantly mild to moderate, most common during dose escalation, and tends to diminish substantially with continued treatment. In STEP 1, fewer than 5% of patients discontinued due to nausea.

Vomiting occurs in 5-24% of patients depending on dose, with higher rates at the 2.4 mg weight management dose. Like nausea, it is most common during dose escalation and usually transient.

Diarrhea is reported in 8-30% of patients, is usually mild, and is typically self-limiting.

Constipation occurs in 5-24% of patients and is attributed to slowed GI transit.

Higher incidences in Wegovy reflect the higher maintenance dose (2.4 mg vs 1 mg).

Dose Escalation and GI Tolerability#

The dose escalation schedules for all semaglutide formulations were specifically designed to minimize GI adverse events. Starting at sub-therapeutic doses (0.25 mg for injectable, 3 mg for oral) and increasing gradually allows physiological adaptation to GLP-1 receptor activation.

Key principles:

• Most GI adverse events occur in the first weeks after each dose increase
• Symptoms typically diminish by weeks 3-4 at each dose level
• Patients who cannot tolerate a dose increase may extend the time at the current dose
• Slower escalation significantly reduces nausea and vomiting incidence

Heart Rate Effects#

Semaglutide is associated with a modest increase in resting heart rate, typically 2-4 beats per minute. This is a GLP-1 agonist class effect and is generally not clinically significant. The mechanism involves direct GLP-1R activation in the sinoatrial node.

Injection Site Reactions#

For injectable formulations, injection site reactions (erythema, pruritus, pain) are reported in approximately 0.2-1% of patients and are generally mild. Rotating injection sites and allowing the pen to reach room temperature before injection can minimize these reactions.

Hepatobiliary Effects#

Cholelithiasis and cholecystitis are reported more frequently with semaglutide than placebo, particularly in weight management trials. In STEP 1, cholelithiasis was reported in 1.6% of semaglutide patients versus 0.7% placebo. Rapid weight loss increases gallstone risk through multiple mechanisms including bile cholesterol supersaturation.

Lipase and amylase elevations are commonly observed during semaglutide treatment without clinical pancreatitis. Isolated enzyme elevations are not considered clinically actionable in the absence of symptoms.

Diabetic Retinopathy#

In SUSTAIN-6, semaglutide was associated with a significant increase in diabetic retinopathy complications (HR 1.76, 95% CI 1.11-2.78). This signal is attributed to rapid HbA1c improvement and has been observed with other intensive glucose-lowering therapies (including insulin). Patients with pre-existing retinopathy, especially proliferative disease, should be monitored during initiation and escalation.

Thyroid Effects (Boxed Warning)#

Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent data. This is a class-wide warning for all GLP-1 agonists. Epidemiologic data over 8+ years have not confirmed this risk in humans, but monitoring continues.

Post-Marketing Signals#

Suicidal ideation: Reports identified through post-marketing surveillance. FDA concluded (2025) that evidence does not establish causation, but investigation continues.

Ileus and intestinal obstruction: Rare reports likely related to significant gastric emptying delay.

Aspiration during anesthesia: Cases reported related to retained gastric contents from gastric emptying delay.

Contraindications#

• MTC or MEN2 history: Absolute contraindication (boxed warning)
• Pregnancy: May cause fetal harm; discontinue at least 2 months before planned conception
• Known hypersensitivity: Prior serious allergic reaction to semaglutide or excipients

Drug Interactions#

Insulin and sulfonylureas: Most important interaction. Increased hypoglycemia risk requires dose reduction of concomitant agents.

Oral contraceptives: Gastric emptying delay may reduce absorption. Consider non-oral contraception during initiation and dose escalation.

Oral medications generally: Delayed gastric emptying may affect absorption kinetics of co-administered oral drugs. Particularly relevant for drugs with narrow therapeutic indices (warfarin, digoxin, levothyroxine).

Rybelsus-specific: The SNAC absorption enhancer requires specific fasting conditions. Other oral medications should not be taken within 30 minutes of Rybelsus administration.

CYP interactions: Semaglutide is not metabolized by CYP enzymes and does not inhibit or induce CYP isoforms. CYP-mediated pharmacokinetic interactions are not expected.

Special Populations#

• Renal impairment: No dose adjustment required. Monitor for dehydration-related AKI during GI adverse events.
• Hepatic impairment: No dose adjustment required.
• Elderly (≥65): No dose adjustment required. Comparable efficacy and safety in clinical trials.
• Pediatric: Semaglutide is approved for adolescents aged 12+ for T2D (Ozempic) in some jurisdictions. Obesity indication in adolescents is under investigation.

Related Reading#

• Semaglutide overview and research guide
• Semaglutide dosing protocols
• Semaglutide risks and legal status